YU401A - Agents with an antidepressive effect - Google Patents

Agents with an antidepressive effect

Info

Publication number
YU401A
YU401A YU401A YU401A YU401A YU 401 A YU401 A YU 401A YU 401 A YU401 A YU 401A YU 401 A YU401 A YU 401A YU 401 A YU401 A YU 401A
Authority
YU
Yugoslavia
Prior art keywords
agents
antidepressive effect
antidepressive
effect
benzothizole
Prior art date
Application number
YU401A
Other languages
Serbo-Croatian (sh)
Inventor
Jerzy Maj
Original Assignee
Boehringer Ingelheim Pharma Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Kg. filed Critical Boehringer Ingelheim Pharma Kg.
Publication of YU401A publication Critical patent/YU401A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the use of 2-amino-4,5,6,7-tetrahydro-6-propylamino-benzothizole (pramipexol), its (+) or (-) enantiomers or one of its pharmacologically compatible salts, combined with sertralin, for treating depression and depressive conditions more effectively.
YU401A 1998-07-07 1999-07-02 Agents with an antidepressive effect YU401A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19830201A DE19830201A1 (en) 1998-07-07 1998-07-07 Antidepressant

Publications (1)

Publication Number Publication Date
YU401A true YU401A (en) 2003-10-31

Family

ID=7873155

Family Applications (1)

Application Number Title Priority Date Filing Date
YU401A YU401A (en) 1998-07-07 1999-07-02 Agents with an antidepressive effect

Country Status (33)

Country Link
US (1) US6255329B1 (en)
EP (1) EP1093369B1 (en)
JP (1) JP2002520273A (en)
KR (1) KR100557692B1 (en)
CN (1) CN1230168C (en)
AR (1) AR019896A1 (en)
AT (1) ATE228365T1 (en)
AU (1) AU762128B2 (en)
BG (1) BG64972B1 (en)
BR (1) BR9911768A (en)
CA (1) CA2336833C (en)
CZ (1) CZ294087B6 (en)
DE (2) DE19830201A1 (en)
DK (1) DK1093369T3 (en)
EA (1) EA003142B1 (en)
EE (1) EE04296B1 (en)
ES (1) ES2183583T3 (en)
HK (1) HK1037976A1 (en)
HU (1) HUP0103922A3 (en)
ID (1) ID27776A (en)
IL (1) IL140603A0 (en)
MY (1) MY117969A (en)
NO (1) NO20010064L (en)
NZ (1) NZ509729A (en)
PL (1) PL195043B1 (en)
PT (1) PT1093369E (en)
RS (1) RS49795B (en)
SK (1) SK284923B6 (en)
TR (1) TR200100146T2 (en)
TW (1) TW592698B (en)
WO (1) WO2000002542A2 (en)
YU (1) YU401A (en)
ZA (1) ZA200100090B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301899C (en) * 1998-07-27 2008-11-18 Boehringer Ingelheim Pharma Kg Agent with an antidepressant activity
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
DE10138275A1 (en) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Connections to eliminate anhedonia
ATE480235T1 (en) * 2001-12-11 2010-09-15 Univ Virginia USE OF PRAMIPEXOLE TO TREAT AMYOTROPHIC LATERAL SCLERosis
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
DE10334188B4 (en) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Use of rotigotine to treat depression
DE10334187A1 (en) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituted 2-aminotetralins for the treatment of depression
JP2007518754A (en) * 2004-01-22 2007-07-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical composition comprising a monoamine neurotransmitter reuptake inhibitor and a dopamine agonist
JP2009504748A (en) * 2005-08-15 2009-02-05 ユニバーシティ オブ バージニア パテント ファウンデーション Nerve recovery with R (+) pramipexole
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
KR20090021169A (en) 2006-05-16 2009-02-27 크놉 뉴로사이언시스 인코포레이티드 Compositions of r(+) and s(-) pramipexole and methods of using the same
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
WO2008113056A2 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
US20080254117A1 (en) * 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
EP2334185A4 (en) * 2008-08-19 2011-09-21 Knopp Neurosciences Inc Compositions and methods of using (r)-pramipexole
ES2459322T3 (en) 2008-09-05 2014-05-09 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit hyperactivity disorder (ADHD)
WO2010127120A1 (en) * 2009-04-30 2010-11-04 Supernus Pharmaceuticals, Inc. Method of treatment of depression
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9358204B2 (en) 2012-02-08 2016-06-07 Supernus Pharmaceuticals, Inc. Formulations of viloxazine
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
PL3019167T3 (en) 2013-07-12 2021-06-14 Knopp Biosciences Llc Treating elevated levels of eosinophils and/or basophils
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES2813674T3 (en) 2013-08-13 2021-03-24 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
HUE055850T2 (en) 2013-08-13 2022-01-28 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
IL269875B2 (en) 2017-04-10 2024-06-01 Chase Therapeutics Corp Nk1-antagonist combination and method for treating synucleinopathies
CN111032158A (en) 2017-06-30 2020-04-17 才思治疗公司 NK-1 antagonist compositions and methods for treating depression
CN110028464B (en) * 2019-04-26 2022-11-18 浙江海洋大学 Antarctic fungus secondary metabolism derivative BTZ-one and preparation method and application thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
EP0186087B1 (en) * 1984-12-22 1989-08-23 Dr. Karl Thomae GmbH Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
DE3843227A1 (en) * 1988-12-22 1990-07-05 Boehringer Ingelheim Kg Use of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
DE3937271A1 (en) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg TRANSDERMAL APPLICATION OF 2-AMINO-6-N-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLE
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
DE4241013A1 (en) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Use of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole as antidepressant drug
JP3947582B2 (en) * 1995-08-15 2007-07-25 中外製薬株式会社 Anxiety treatment
TR199801929T2 (en) * 1996-03-29 1998-12-21 Pfizer Inc. Benzyl(ide)-lactam derivatives, their use as (anti)agonists of the 5-HT1A receptors.
JP2001507678A (en) * 1996-12-02 2001-06-12 メルク シヤープ エンド ドーム リミテツド Use of an NK-1 receptor antagonist for the treatment of movement disorders
WO1999036064A2 (en) * 1998-01-13 1999-07-22 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders

Also Published As

Publication number Publication date
WO2000002542A3 (en) 2000-06-22
ID27776A (en) 2001-04-26
SK112001A3 (en) 2001-10-08
WO2000002542A2 (en) 2000-01-20
DK1093369T3 (en) 2002-12-16
EA003142B1 (en) 2003-02-27
EE200100014A (en) 2002-06-17
ATE228365T1 (en) 2002-12-15
ZA200100090B (en) 2002-04-04
IL140603A0 (en) 2002-02-10
KR20010079491A (en) 2001-08-22
HUP0103922A3 (en) 2002-08-28
NO20010064L (en) 2001-03-02
CZ200177A3 (en) 2001-06-13
CN1308533A (en) 2001-08-15
BG105112A (en) 2001-10-31
EE04296B1 (en) 2004-06-15
BG64972B1 (en) 2006-11-30
TR200100146T2 (en) 2001-07-23
PL195043B1 (en) 2007-08-31
MY117969A (en) 2004-08-30
BR9911768A (en) 2001-04-03
HUP0103922A2 (en) 2002-03-28
EP1093369B1 (en) 2002-11-27
CZ294087B6 (en) 2004-10-13
AU5030399A (en) 2000-02-01
EP1093369A2 (en) 2001-04-25
HK1037976A1 (en) 2002-03-01
TW592698B (en) 2004-06-21
ES2183583T3 (en) 2003-03-16
NZ509729A (en) 2003-06-30
AR019896A1 (en) 2002-03-20
CA2336833C (en) 2008-09-23
KR100557692B1 (en) 2006-03-07
AU762128B2 (en) 2003-06-19
JP2002520273A (en) 2002-07-09
CA2336833A1 (en) 2000-01-20
DE19830201A1 (en) 2000-01-13
CN1230168C (en) 2005-12-07
US6255329B1 (en) 2001-07-03
EA200100084A1 (en) 2001-08-27
SK284923B6 (en) 2006-02-02
NO20010064D0 (en) 2001-01-05
DE59903556D1 (en) 2003-01-09
RS49795B (en) 2008-06-05
PL345842A1 (en) 2002-01-14
PT1093369E (en) 2003-03-31

Similar Documents

Publication Publication Date Title
YU401A (en) Agents with an antidepressive effect
CA2301899A1 (en) Agent with an antidepressant activity
RS50091B (en) Use of retigabine for the treatment of neuropathic pain
MXPA02000973A (en) Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists.
BR0007527A (en) Phenylphenanthridines with IV-dependent inhibitory activity
BG106586A (en) Pyrazolopyramidines as therapeutic agents
BG104247A (en) Resorcinol derivatives
NO20013444D0 (en) Triazole compounds with the dopamine D3 receptor affinity
BG104780A (en) Inhibitors of phospholipase enzymes
DE60112974D1 (en) Carbolinderivate
YU19499A (en) Benzonaphthyridines as bronchial therapeutics
DE59914814D1 (en) Heterocyclic substituted amides, their preparation and their use
DE60216233D1 (en) Carbolinderivate
MXPA02010088A (en) Antitumoral ecteinascidin derivatives.
NO20005290D0 (en) Riluzole and levodopa combinations for the treatment of Parkinson's disease
SI1086096T1 (en) Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors
DE60233350D1 (en) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
BR9914848A (en) Composition and process for the treatment of disorders of the external retina
BG105710A (en) 5ht1 antagonists for antidepressant therapy
YU18801A (en) Eletriptan hydrobromide monohydrate
IL142803A0 (en) Pharmaceutical compositions containing r-tofisopam
BR0012751A (en) Serotonergic benzofurans
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
IL139303A0 (en) Treatment of arthritis and other similar conditions
ATE373475T1 (en) CARBAMATES OF 2-HETEROCYCLIC 1,2-ETHANEDIOLS